Immune targeting of the microenvironment in classical Hodgkin’s lymphoma: insights for the hematologist

While up to 80% of patients with Hodgkin’s lymphoma (HL) are cured with first-line therapy, relapsed/refractory (R/R) disease remains a clinical challenge and is fatal for many young patients. HL is unique in that the tumor cells (Hodgkin Reed–Sternberg; HRS cells) are a small fraction (<1%) of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Carreau, Nicole A., Diefenbach, Catherine S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501496/
https://www.ncbi.nlm.nih.gov/pubmed/31105921
http://dx.doi.org/10.1177/2040620719846451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501496/
https://www.ncbi.nlm.nih.gov/pubmed/31105921
http://dx.doi.org/10.1177/2040620719846451

Ejemplares similares